Bone remodeling during alveolar repair is impaired by RANKL antagonist
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/11975 |
Resumo: | Post-menopausal osteoporosis is detrimental to bone metabolism as well as alveolar repair. This osteometabolic disorder is an obstacle to the success of maxillofacial rehabilitations, since a large number of patients are carriers of the disease. Denosumab is widely used as a treatment for post menopausal osteoporosis. This drug exerts an antiabsorptive action by inhibiting RANKL, helping to reduce the bone loss caused by osteoporosis. This study aimed to evaluate the repair bone formed after the extraction of the upper incisor of estrogen-deficient rats treated with anti-RANKL monoclonal antibody. The rats (Rattus novergicus albinus, Wistar) were ovariectomized or SHAM operated (n=36). Half of the ovariectomized rats were treated with osteoprotegerin with an Fc fragment (OPG-Fc; 10mg/kg, twice a week), the other half received saline solution as control. After 30 days the rats had their right upper incisor extracted. After 60 days of extraction, the alveoli were evaluated by immunohistochemical, computerized microtomography and confocal microscopy. The OPG-Fc decreased the percentage of bone volume (BV/TV), thickness (Tb.Th) and number of alveolar trabecules (Tb.N) when compared to groups that received saline solution (p<0.005). The OPG-Fc increased the separation between the trabecules (Tb.Sp) and the porosity (Po.tot) of the reparative alveolar bone (p<0.005). The OPG-Fc decreased immunolabelling for RANKL and TRAP when compared to groups that received saline solution. Treatment with OPG-Fc decreased bone neoformation but preserved preexisting bone tissue. This data is supported by the mineral apposition rate, which showed higher values for OVX/OPG-Fc when compared to the OVX group. |
id |
UNIFEI_37430cc17038408350c8faaf62dec5b8 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/11975 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Bone remodeling during alveolar repair is impaired by RANKL antagonistLa remodelación ósea durante la reparación alveolar se ve afectada por el antagonista de RANKLRemodelação óssea durante o reparo alveolar é prejudicada por antagonista da RANKLOsteoporoseRemodelação ósseaDensidade ósseaAlvéolo dentalDenosumab.OsteoporosisRemodelación óseaDensidad oseaAlvéolo dentalDenosumab.OsteoporosisBone remodelingBone densityTooth socketDenosumab.Post-menopausal osteoporosis is detrimental to bone metabolism as well as alveolar repair. This osteometabolic disorder is an obstacle to the success of maxillofacial rehabilitations, since a large number of patients are carriers of the disease. Denosumab is widely used as a treatment for post menopausal osteoporosis. This drug exerts an antiabsorptive action by inhibiting RANKL, helping to reduce the bone loss caused by osteoporosis. This study aimed to evaluate the repair bone formed after the extraction of the upper incisor of estrogen-deficient rats treated with anti-RANKL monoclonal antibody. The rats (Rattus novergicus albinus, Wistar) were ovariectomized or SHAM operated (n=36). Half of the ovariectomized rats were treated with osteoprotegerin with an Fc fragment (OPG-Fc; 10mg/kg, twice a week), the other half received saline solution as control. After 30 days the rats had their right upper incisor extracted. After 60 days of extraction, the alveoli were evaluated by immunohistochemical, computerized microtomography and confocal microscopy. The OPG-Fc decreased the percentage of bone volume (BV/TV), thickness (Tb.Th) and number of alveolar trabecules (Tb.N) when compared to groups that received saline solution (p<0.005). The OPG-Fc increased the separation between the trabecules (Tb.Sp) and the porosity (Po.tot) of the reparative alveolar bone (p<0.005). The OPG-Fc decreased immunolabelling for RANKL and TRAP when compared to groups that received saline solution. Treatment with OPG-Fc decreased bone neoformation but preserved preexisting bone tissue. This data is supported by the mineral apposition rate, which showed higher values for OVX/OPG-Fc when compared to the OVX group.La osteoporosis posmenopáusica es perjudicial para el metabolismo óseo y la reparación alveolar. Este trastorno osteometabólico es un obstáculo para el éxito de las rehabilitaciones maxilofaciales, ya que un gran número de pacientes son portadores de la enfermedad. El denosumab se usa ampliamente como tratamiento para la osteoporosis posmenopáusica. Este fármaco ejerce una acción antiabsorbente al inhibir RANKL, ayudando a reducir la pérdida ósea provocada por la osteoporosis. Este estudio tuvo como objetivo evaluar el hueso de reparación formado tras la extracción del incisivo superior de ratas deficientes en estrógenos tratadas con anticuerpo monoclonal anti-RANKL. Las ratas (Rattus novergicus albinus, Wistar) fueron ovariectomizadas u operadas con SHAM (n = 36). La mitad de las ratas ovariectomizadas fueron tratadas con osteoprotegerina con un fragmento Fc (OPG-Fc; 10 mg / kg, dos veces por semana), la otra mitad recibió solución salina como control. Después de 30 días, se extrajo el incisivo superior derecho de las ratas. Después de 60 días de extracción, los alvéolos fueron evaluados por inmunohistoquímica, microtomografía computarizada y microscopía confocal. La OPG-Fc disminuyó el porcentaje de volumen óseo (BV / TV), grosor (Tb.Th) y número de trabéculas alveolares (Tb.N) en comparación con los grupos que recibieron solución salina (p <0,005). La OPG-Fc aumentó la separación entre las trabéculas (Tb.Sp) y la porosidad (Po.tot) del hueso alveolar reparador (p <0,005). El OPG-Fc disminuyó el inmunomarcaje de RANKL y TRAP en comparación con los grupos que recibieron solución salina. El tratamiento con OPG-Fc disminuyó la neoformación ósea pero conservó el tejido óseo preexistente. Estos datos están respaldados por la tasa de aposición de minerales, que mostró valores más altos para OVX / OPG-Fc en comparación con el grupo OVX.A osteoporose pós menopáusica é prejudicial ao metabolismo ósseo, bem como ao reparo alveolar. Essa desordem osteometabólica é um obstáculo para o sucesso das reabilitações maxilofaciais, visto que uma grande parcela dos pacientes são portadores da doença. O Denosumab é amplamente utilizado como tratamento da osteoporose pós menopáusica. Esse medicamento exerce ação antireabsortiva pela inibição do RANKL, auxiliando na diminuição da perda óssea provocada pela osteoporose. Este estudo teve como objetivo a avaliação do osso reparacional formado após a exodontia do incisivo superior de ratas com deficiência de estrógeno tratadas com o anticorpo monoclonal anti-RANKL. As ratas (Rattus novergicus albinus, Wistar) foram ovariectomizadas ou SHAM operadas (n=36). Metade das ratas ovariectomizadas receberam tratamento com osteoprotegerina com um fragmento Fc (OPG-Fc; 10mg/kg, duas vezes por semana), o restante das ratas recebeu solução salina como controle. Após 30 dias as ratas tiveram o incisivo superior direito extraído. Decorridos 60 dias da exodontia, os alvéolos foram avaliados por imunoistoquímica, microtomografia computadorizada e microscopia confocal. A OPG-Fc diminuiu a porcentagem de volume ósseo (BV/TV), espessura (Tb.Th) o número das trabéculas (Tb.N) alveolares quando em comparação aos grupos que receberam solução salina (p<0,005). A OPG-Fc aumentou a separação entre as trabéculas (Tb.Sp) e a porosidade (Po.tot) do osso alveolar reparacional (p<0,005). A OPG-Fc diminuiu a imunomarcação para RANKL e TRAP quando comparada aos grupos que receberam solução salina. O tratamento com OPG-Fc diminuiu a neoformação óssea, mas preservou o tecido ósseo preexistente. Esse dado é suportado pela taxa de aposição mineral, que apresentou valores maiores para OVX/OPG-Fc quando comparado ao grupo OVX.Research, Society and Development2021-01-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1197510.33448/rsd-v10i1.11975Research, Society and Development; Vol. 10 No. 1; e43710111975Research, Society and Development; Vol. 10 Núm. 1; e43710111975Research, Society and Development; v. 10 n. 1; e437101119752525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/11975/10762Copyright (c) 2021 Ana Cláudia Ervolino da Silva; Fábio Roberto de Souza Batista; Juliana de Moura; Juliana Zorzi Coléte; Fernando Chiba; Pedro Henrique Silva Gomes-Ferreira; Roberta Okamotohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Ana Cláudia Ervolino da Batista, Fábio Roberto de Souza Moura, Juliana de Coléte, Juliana Zorzi Chiba, Fernando Gomes-Ferreira, Pedro Henrique Silva Okamoto, Roberta 2021-02-20T21:19:23Zoai:ojs.pkp.sfu.ca:article/11975Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:33:40.257415Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Bone remodeling during alveolar repair is impaired by RANKL antagonist La remodelación ósea durante la reparación alveolar se ve afectada por el antagonista de RANKL Remodelação óssea durante o reparo alveolar é prejudicada por antagonista da RANKL |
title |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
spellingShingle |
Bone remodeling during alveolar repair is impaired by RANKL antagonist Silva, Ana Cláudia Ervolino da Osteoporose Remodelação óssea Densidade óssea Alvéolo dental Denosumab. Osteoporosis Remodelación ósea Densidad osea Alvéolo dental Denosumab. Osteoporosis Bone remodeling Bone density Tooth socket Denosumab. |
title_short |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
title_full |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
title_fullStr |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
title_full_unstemmed |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
title_sort |
Bone remodeling during alveolar repair is impaired by RANKL antagonist |
author |
Silva, Ana Cláudia Ervolino da |
author_facet |
Silva, Ana Cláudia Ervolino da Batista, Fábio Roberto de Souza Moura, Juliana de Coléte, Juliana Zorzi Chiba, Fernando Gomes-Ferreira, Pedro Henrique Silva Okamoto, Roberta |
author_role |
author |
author2 |
Batista, Fábio Roberto de Souza Moura, Juliana de Coléte, Juliana Zorzi Chiba, Fernando Gomes-Ferreira, Pedro Henrique Silva Okamoto, Roberta |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Ana Cláudia Ervolino da Batista, Fábio Roberto de Souza Moura, Juliana de Coléte, Juliana Zorzi Chiba, Fernando Gomes-Ferreira, Pedro Henrique Silva Okamoto, Roberta |
dc.subject.por.fl_str_mv |
Osteoporose Remodelação óssea Densidade óssea Alvéolo dental Denosumab. Osteoporosis Remodelación ósea Densidad osea Alvéolo dental Denosumab. Osteoporosis Bone remodeling Bone density Tooth socket Denosumab. |
topic |
Osteoporose Remodelação óssea Densidade óssea Alvéolo dental Denosumab. Osteoporosis Remodelación ósea Densidad osea Alvéolo dental Denosumab. Osteoporosis Bone remodeling Bone density Tooth socket Denosumab. |
description |
Post-menopausal osteoporosis is detrimental to bone metabolism as well as alveolar repair. This osteometabolic disorder is an obstacle to the success of maxillofacial rehabilitations, since a large number of patients are carriers of the disease. Denosumab is widely used as a treatment for post menopausal osteoporosis. This drug exerts an antiabsorptive action by inhibiting RANKL, helping to reduce the bone loss caused by osteoporosis. This study aimed to evaluate the repair bone formed after the extraction of the upper incisor of estrogen-deficient rats treated with anti-RANKL monoclonal antibody. The rats (Rattus novergicus albinus, Wistar) were ovariectomized or SHAM operated (n=36). Half of the ovariectomized rats were treated with osteoprotegerin with an Fc fragment (OPG-Fc; 10mg/kg, twice a week), the other half received saline solution as control. After 30 days the rats had their right upper incisor extracted. After 60 days of extraction, the alveoli were evaluated by immunohistochemical, computerized microtomography and confocal microscopy. The OPG-Fc decreased the percentage of bone volume (BV/TV), thickness (Tb.Th) and number of alveolar trabecules (Tb.N) when compared to groups that received saline solution (p<0.005). The OPG-Fc increased the separation between the trabecules (Tb.Sp) and the porosity (Po.tot) of the reparative alveolar bone (p<0.005). The OPG-Fc decreased immunolabelling for RANKL and TRAP when compared to groups that received saline solution. Treatment with OPG-Fc decreased bone neoformation but preserved preexisting bone tissue. This data is supported by the mineral apposition rate, which showed higher values for OVX/OPG-Fc when compared to the OVX group. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-01-24 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/11975 10.33448/rsd-v10i1.11975 |
url |
https://rsdjournal.org/index.php/rsd/article/view/11975 |
identifier_str_mv |
10.33448/rsd-v10i1.11975 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/11975/10762 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 1; e43710111975 Research, Society and Development; Vol. 10 Núm. 1; e43710111975 Research, Society and Development; v. 10 n. 1; e43710111975 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052668740370432 |